| Product Code: ETC088680 | Publication Date: Jun 2021 | Updated Date: Aug 2025 | Product Type: Report | |
| Publisher: 6Wresearch | Author: Ravi Bhandari | No. of Pages: 70 | No. of Figures: 35 | No. of Tables: 5 |
The radiopharmaceutical market in Qatar is still relatively small compared to the rest of the Middle East. The value of radiopharmaceuticals sales in Qatar was estimated at USD 3. 9 million in 2018 and is expected to reach USD 7. 8 million by 2025, achieving a CAGR of 9. 1% during the forecast period. As one of the leading suppliers for medical isotopes used for diagnosis and therapy globally, Qatar supplies most radioisotopes in this region through its sole supplier ? Qatar Nuclear Research Centre (QNRC).
The Qatar radiopharmaceutical market is influenced by the rising emphasis on healthcare and medical advancements. Radiopharmaceuticals play a crucial role in diagnostic and therapeutic procedures, enabling accurate disease diagnosis and targeted treatments. The Qatar government`s focus on improving healthcare infrastructure and services is contributing to the growth of the radiopharmaceutical market. Additionally, the aging population and the prevalence of chronic diseases are driving the demand for advanced medical imaging and treatments, creating a favorable environment for radiopharmaceuticals. As Qatar strives to enhance its healthcare capabilities, the radiopharmaceutical market is poised to grow, supported by the integration of modern medical technologies.
The Qatar radiopharmaceutical market operates at the intersection of healthcare, pharmaceuticals, and nuclear technology, and it faces specific challenges that impact its growth and utilization. Radiopharmaceuticals play a critical role in medical imaging, diagnosis, and therapy. One of the challenges in this market is the complex regulatory environment associated with the use of radioactive materials in medical applications. Ensuring safety, compliance, and proper disposal of radioactive waste are paramount concerns that require rigorous adherence to international standards and regulations.
The Qatar radiopharmaceutical market, operating at the intersection of healthcare and nuclear technology, faced unique challenges due to the COVID-19 pandemic. The pandemic strained healthcare resources and disrupted routine medical procedures, impacting the demand for radiopharmaceuticals. Delayed or rescheduled medical imaging and diagnostic procedures affected the market`s dynamics. Additionally, global travel restrictions impacted the supply chain and availability of certain radiopharmaceuticals with shorter half-lives. As Qatar strives to restore healthcare services and manage the pandemic`s aftermath, close collaboration between healthcare institutions, regulatory bodies, and research organizations will play a pivotal role in revitalizing the radiopharmaceutical market.
Key players in the Qatar radiopharmaceutical market include Qatar Radioactive Medical Waste Management Company and Hamad Medical Corporation. Qatar Radioactive Medical Waste Management Company is responsible for the safe disposal of radioactive waste generated from medical applications, ensuring compliance with international standards. Hamad Medical Corporation, the leading healthcare provider in Qatar, plays a vital role in the distribution and administration of radiopharmaceuticals for diagnostic and therapeutic purposes. These key players contribute to Qatar healthcare sector by ensuring the safe utilization of radiopharmaceuticals for medical advancements.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Qatar Radiopharmaceutical Market Overview |
3.1 Qatar Country Macro Economic Indicators |
3.2 Qatar Radiopharmaceutical Market Revenues & Volume, 2021 & 2031F |
3.3 Qatar Radiopharmaceutical Market - Industry Life Cycle |
3.4 Qatar Radiopharmaceutical Market - Porter's Five Forces |
3.5 Qatar Radiopharmaceutical Market Revenues & Volume Share, By Types, 2021 & 2031F |
3.6 Qatar Radiopharmaceutical Market Revenues & Volume Share, By Applications, 2021 & 2031F |
3.7 Qatar Radiopharmaceutical Market Revenues & Volume Share, By Procedural Volume Assessment, 2021 & 2031F |
3.8 Qatar Radiopharmaceutical Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.9 Qatar Radiopharmaceutical Market Revenues & Volume Share, By End-users, 2021 & 2031F |
4 Qatar Radiopharmaceutical Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Growing prevalence of cancer and other chronic diseases requiring nuclear medicine diagnostics and therapies |
4.2.2 Increasing investments in healthcare infrastructure and technology in Qatar |
4.2.3 Rising awareness about the benefits of nuclear medicine and radiopharmaceuticals |
4.3 Market Restraints |
4.3.1 Stringent regulations and lengthy approval processes for radiopharmaceutical products |
4.3.2 Limited availability and high cost of advanced radiopharmaceutical manufacturing technologies in Qatar |
5 Qatar Radiopharmaceutical Market Trends |
6 Qatar Radiopharmaceutical Market, By Types |
6.1 Qatar Radiopharmaceutical Market, By Types |
6.1.1 Overview and Analysis |
6.1.2 Qatar Radiopharmaceutical Market Revenues & Volume, By Types, 2021-2031F |
6.1.3 Qatar Radiopharmaceutical Market Revenues & Volume, By Diagnostic Nuclear Medicine, 2021-2031F |
6.1.4 Qatar Radiopharmaceutical Market Revenues & Volume, By Therapeutic Nuclear Medicine, 2021-2031F |
6.2 Qatar Radiopharmaceutical Market, By Applications |
6.2.1 Overview and Analysis |
6.2.2 Qatar Radiopharmaceutical Market Revenues & Volume, By Diagnostic Applications, 2021-2031F |
6.2.3 Qatar Radiopharmaceutical Market Revenues & Volume, By Therapeutic Applications, 2021-2031F |
6.3 Qatar Radiopharmaceutical Market, By Procedural Volume Assessment |
6.3.1 Overview and Analysis |
6.3.2 Qatar Radiopharmaceutical Market Revenues & Volume, By Diagnostic Procedures, 2021-2031F |
6.3.3 Qatar Radiopharmaceutical Market Revenues & Volume, By Therapeutic Procedures, 2021-2031F |
6.4 Qatar Radiopharmaceutical Market, By Source |
6.4.1 Overview and Analysis |
6.4.2 Qatar Radiopharmaceutical Market Revenues & Volume, By Nuclear Reactors, 2021-2031F |
6.4.3 Qatar Radiopharmaceutical Market Revenues & Volume, By Cyclotrons, 2021-2031F |
6.5 Qatar Radiopharmaceutical Market, By End-users |
6.5.1 Overview and Analysis |
6.5.2 Qatar Radiopharmaceutical Market Revenues & Volume, By Hospitals, 2021-2031F |
6.5.3 Qatar Radiopharmaceutical Market Revenues & Volume, By Ambulatory Surgical Centers, 2021-2031F |
6.5.4 Qatar Radiopharmaceutical Market Revenues & Volume, By Diagnostic Centers, 2021-2031F |
6.5.5 Qatar Radiopharmaceutical Market Revenues & Volume, By Cancer Research Institutes, 2021-2031F |
6.5.6 Qatar Radiopharmaceutical Market Revenues & Volume, By Others, 2021-2031F |
7 Qatar Radiopharmaceutical Market Import-Export Trade Statistics |
7.1 Qatar Radiopharmaceutical Market Export to Major Countries |
7.2 Qatar Radiopharmaceutical Market Imports from Major Countries |
8 Qatar Radiopharmaceutical Market Key Performance Indicators |
8.1 Number of new nuclear medicine facilities established in Qatar |
8.2 Investment in research and development of radiopharmaceutical products in the country |
8.3 Percentage increase in the number of trained professionals in the field of nuclear medicine in Qatar |
9 Qatar Radiopharmaceutical Market - Opportunity Assessment |
9.1 Qatar Radiopharmaceutical Market Opportunity Assessment, By Types, 2021 & 2031F |
9.2 Qatar Radiopharmaceutical Market Opportunity Assessment, By Applications, 2021 & 2031F |
9.3 Qatar Radiopharmaceutical Market Opportunity Assessment, By Procedural Volume Assessment, 2021 & 2031F |
9.4 Qatar Radiopharmaceutical Market Opportunity Assessment, By Source, 2021 & 2031F |
9.5 Qatar Radiopharmaceutical Market Opportunity Assessment, By End-users, 2021 & 2031F |
10 Qatar Radiopharmaceutical Market - Competitive Landscape |
10.1 Qatar Radiopharmaceutical Market Revenue Share, By Companies, 2024 |
10.2 Qatar Radiopharmaceutical Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |